Oura Postpones IPO After Roadshow, Citing Market Uncertainty

Oura CEO Tom Hale delayed the company's IPO on Sept. 29, after a much-anticipated roadshow, citing "uncertainty in the IPO market." The smart ring maker had proposed selling 50 million shares at $40 to $44 apiece, targeting a fully diluted valuation of $15.6 billion at the top of the range.

Fortune's Allie Garfinkle, who had previously reported on the pending IPO, acknowledged the reversal: "I was wrong." She had written that, in the AI era, Oura looked like the company investors could rely on to take the go-public plunge.

Fortune reporter Morgan Chittum examined why Oura got so close to the listing and then backed off at the last minute. Her reporting points to two main factors: a contested valuation and a deal structure tilted toward existing shareholders.

Was the $15.6 billion valuation too high?

At the $42 midpoint of the proposed range, the deal would have raised roughly $2.1 billion in gross proceeds, Chittum reported. But the number may have been hard to justify for a company whose core product is an electronic ring.

"If you are viewing Oura as an AI-enabled digital-health platform … then whatever multiple they are looking for can kind of be justified," said Kat Siu, vice president of financial services firm IPOX. "But if you are just looking at them as a pure ring manufacturer, just consumer hardware, then that valuation is pretty hefty."

The distinction matters because Oura's sales still lean heavily toward hardware, according to Siu. Oura has tried to sell itself as more than a smart ring, leveraging its massive data set and AI tie-ins as part of a broader narrative.

Why did the deal structure worry investors?

The offering's composition may also have given investors pause. Of the 50 million shares proposed:

• Only 13.5 million, or 27%, were to be newly issued by Oura.
• The other 36.5 million, or 73% of the deal, were to be sold by existing shareholders.

At the $42 midpoint, that works out to roughly $567 million in gross proceeds for Oura and approximately $1.53 billion for selling shareholders. The bulk of the cash raised would have gone to early investors and insiders rather than to the company.

That split raised the prospect of heavy initial selling, which can make an IPO look less like a fundraise and more like a liquidity event for existing investors.

"That's a flag for the market," Siu said. "It's signaling that this IPO is not meant for growth."

What happens next?

Oura also faces competition from giants like Apple. Garfinkle wrote that she sincerely thought the company would dive into the IPO waters — and offered a mea culpa for the missed call.

The company said it was "postponing" the offering, but gave no indication of when it might try again. A retry is possible, maybe even likely, according to Garfinkle.

The broader IPO market, she wrote, has been "perennially on the edge of something happening for months — and it looks like we may be in suspended animation for a while still." For Oura, that means the $15.6 billion question of whether investors will ever price it as a digital-health platform rather than a hardware maker remains open.